Form 10-Q REGENERON PHARMACEUTICAL For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street rises on Iran war peace deal hopes, SpaceX's historic debut
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil nears two-month lows on reports of imminent US-Iran peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Regeneron Pharma (REGN) PT Lowered to $880 at Leerink Partners
November 1, 2024 7:19 AM EDTLeerink Partners analyst Andrew Berens lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $880.00 (from $1,077.00) while maintaining a Market Perform rating.
The analyst comments "Bottom Line: We are reducing our REGN PT from $1,077 (22x old 2025E EPS of $48.96) to $880 (20x new 2025E EPS of $44.01). We... More
Regeneron Pharma (REGN) PT Lowered to $1,170 at Evercore ISI
October 31, 2024 4:35 PM EDTEvercore ISI analyst Cory Kasimov lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,170.00 (from $1,175.00) while maintaining a Outperform rating.
The analyst comments "Its been all tricks and no treats for REGN. Following todays 3Q print, shares are off another ~10%... More
